Ikaria Holdings, Inc. is a fully integrated critical care therapeutics company formed in March 2007 through the combination of INO Therapeutics and Ikaria. INO, established in 1998, is the leader in FDA-approved pharmaceutical gasses in the United States and is a leading provider of critical care therapy generally. INO's primary product is a medical device and pharmaceutical gas combination used as the standard of care to restore lung function, primarily in neonatal intensive care units. INO currently calls on over 575 hospitals in the United States and over 100,000 patients have been treated with the INO product since its official launch in 2000. Ikaria, founded in 2005, is a development stage pharmaceutical gas and technology company with products under development in a complementary pharmaceutical gas niche that might be highly synergistic with INO's product lines and capabilities.

New Mountain acquired INO and Ikaria proactively and on an exclusively negotiated basis, based on work in the medical device industry which began almost three years before the investment was made. New Mountain formed a strategic alliance with Ikaria to pursue INO in February of 2006 and conducted over eleven months of intensive due diligence work on both INO and Ikaria.

www.ikaria.com